GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Aurora Design PCL (BKK:AURA) » Definitions » Net Intangibles Purchase And Sale

Aurora Design PCL (BKK:AURA) Net Intangibles Purchase And Sale : ฿-2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aurora Design PCL Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Aurora Design PCL's net Intangibles purchase and sale for the three months ended in Mar. 2024 was ฿-1 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2024 was ฿-2 Mil.

Aurora Design PCL Net Intangibles Purchase And Sale Historical Data

The historical data trend for Aurora Design PCL's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurora Design PCL Net Intangibles Purchase And Sale Chart

Aurora Design PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
- -2.38 -5.94 -2.37 -2.25

Aurora Design PCL Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1.02 -0.64 -0.24 -0.35 -0.82

Aurora Design PCL Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurora Design PCL Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Aurora Design PCL's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurora Design PCL (BKK:AURA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Aurora Design PCL (BKK:AURA) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
BKK:JUBILE BKK:PDJ BKK:SAWANG XPAR:MC XPAR:RMS XPAR:CDI XSWX:CFR XPAR:KER NSE:TITAN HKSE:01913 HKSE:01929 XSWX:UHR OCSE:PNDORA LSE:BRBY TPR CPRI MIL:BC BOM:543278 SHSE:600612 SIG
Traded in Other Exchanges
N/A
Address
444 Soi Udomsuk 26, Bang Na Nuea, Bang Na, Bangkok, THA, 10260
Website
https://www.auroradesign.co.th
Aurora Design PCL is thailand based company which engages in the trading of gold jewelry, diamonds, gems and k-gold. and rendering service of sale with rights of redemption for gold jewelry, diamonds, gems and k-gold.

Aurora Design PCL (BKK:AURA) Headlines

From GuruFocus

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

By Business Wire Business Wire • 06-17-2022

Aura Biosciences to Present Preclinical Data Highlighting AU?011's Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

By Business Wire Business Wire • 03-08-2022

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference

By Business Wire Business Wire • 05-03-2022

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

By Business Wire Business Wire • 06-30-2022

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

By Business Wire Business Wire • 02-16-2023

Aura Biosciences to Participate in Upcoming Investor Conferences

By Business Wire Business Wire • 11-03-2022

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

By Business Wire Business Wire • 05-26-2022

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

By Business Wire • 10-02-2023

Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)

By Business Wire Business Wire • 03-21-2022

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

By Business Wire Business Wire • 11-10-2022